Because these treatments are offered to patients who may have subclinical coronary artery disease, it is important to understand the role of GM-CSF in advanced plaque progression.
In theory, both growth factor and non-growth factor roles of GM-CSF could be important in atherosclerosis. In animal models of atherosclerosis, the effects of GM-CSF deficiency or exogenous GM-CSF administration on atherosclerosis have been variable and dependent on the specific animal model tested. 7, 10, 13, 14 However, most of these studies used models and reported end points most relevant to early atherogenesis, such as lesion size and cellularity, not advanced plaque progression. In this regard, most clinically relevant plaques in humans are distinguished not by their large size and cellularity but rather by features of plaque instability, notably plaque necrosis. 15 A major cause of advanced plaque necrosis is accelerated lesional macrophage apoptosis coupled with defective efferocytic clearance of the dead cells, leading to postapoptotic necrosis and necrotic core formation. 16 Advanced plaques are also characterized by excessive oxidative stress, which promotes macrophage apoptosis. 17, 18 To address this gap, we conducted a study in Csf2 −/− Ldlr −/− mice subjected to prolonged Western-type diet (WD) feeding and focused on lesional cell apoptosis and necrotic core formation. We observed that the aortic root lesions of these GM-CSF-deficient mice had a substantial decrease in apoptotic cells, plaque necrosis, and oxidative stress compared with lesions of control Ldlr −/− mice. The mechanism involves GM-CSF-mediated induction of IL-23 in myeloid cells, which then sensitizes macrophages to apoptosis via proteasomal degradation of Bcl-2. The decrease in Bcl-2 increases caspase-9 activation and promotes proapoptotic oxidative stress. Thus, a non-growth factor function of GM-CSF promotes advanced plaque progression through an IL-23-mediated signaling pathway in macrophages that increases their susceptibility to apoptosis. These findings reveal a new pathway that contributes to advanced lesional macrophage apoptosis, which may be relevant to contemplated or actual situations where GM-CSF or IL-23 is used as a treatment modality in humans.
Methods

Animals and Animal Maintenance
Csf2
−/− mice on a C57BL/6J background were generously provided by Dr Bruce Trapnell (University of Cincinnati College of Medicine).
−/− mice were bred with C57BL/6J Ldlr −/− mice (Jackson laboratories) to generate Csf2 
Atherosclerotic Lesion Analysis and Metabolic Profiling
Animals were euthanized at the end of the WD feeding period using isoflurane inhalation, and blood was withdrawn by cardiac puncture. The heart with the aortic root attached was harvested, embedded in optimum cutting temperature and frozen on dry ice. Aortic root sections were prepared using a cryomicrotome and then stained with hematoxylin and eosin. Six sections per mouse were quantified for total lesion area and necrotic area as described previously. 19 Briefly, the intimal region containing lesions is demarcated and quantified using ImagePro Plus by a person blinded to the experimental groups. Similarly, the necrotic area is marked and quantified as an area of the lesion that is devoid of cellular nuclei. Plasma cholesterol and triglycerides were measured using the Cholesterol E kit and Triglyceride M Color B kit from Wako. Fasting blood glucose was measured using glucose test strips and a glucometer. Plasma insulin was analyzed using an insulin ELISA kit (Crystal Chem).
Apoptosis and In Situ Efferocytosis Assays
Apoptosis in cultured macrophages was assayed using Alexa Fluorconjugated annexin-V labeling (Life Technologies), followed by fluorescence microscopy. A total of 600 cells per group were analyzed to quantify the percentage of cells that were annexin-V positive. Apoptosis in atherosclerotic lesions was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining using the tetramethylrhodamine red in situ cell death detection kit (Roche) following the manufacturer's protocol. The TUNELstained sections were analyzed by microscopy and quantification was conducted using ImageJ. Lesional apoptosis was also assayed using activated-caspase-3 immunofluorescence microscopy. 20 In situ efferocytosis quantification was performed as described previously. 21, 22 Briefly, aortic root sections were stained with TUNEL followed by anti-F4/80 immunohistochemistry to label lesional macrophages. Efferocytosis efficiency was quantified by counting the number of apoptotic cells that were colocalized or juxtaposed to F4/80-labeled macrophages (associated) versus those that were not associated with macrophages (free).
Statistics
The data are displayed as mean±SEM. The n numbers for each group are indicated in the figure legends. All data presented in this study fit into a normal distribution and hence a Student 2-tailed t test was used for determining statistical significance between 2 groups, whereas, a 1-way ANOVA with Bonferroni's correction was applied while evaluating statistical significance between multiple groups. The difference between the mean values was considered significant when the P value was <0.05.
Detailed Methods are provided in the Online Data Supplement. ) and control Ldlr −/− mice were fed a WD for 12 weeks. We first confirmed that GM-CSF was absent in the atherosclerotic lesions of Csf2 −/− Ldlr −/− mice (Online Figure I) . Furthermore, we observed no significant differences between the 2 groups of mice in terms of body weight, total cholesterol, plasma triglycerides, fasting blood glucose, or plasma insulin (Online Table I ). When the end point of total aortic root lesional area was assessed, we found that the 2 cohorts were remarkably similar ( Figure 1A and 1B) , which is largely consistent with a previous study. 13 Also consistent with previous studies, 
Results
Aortic Root Lesions of WD-Fed
GM-CSF/IL-23 Macrophage Axis in Plaque Necrosis e15
we observed that lesional macrophages, DCs, and smooth muscle cells were the major producers of GM-CSF in lesions of Ldlr −/− mice (Online Figure II) . Because GM-CSF is an important hematopoietic growth factor, we next analyzed the immune cell distribution in the lesions. Overall plaque cellularity was comparable between the 2 groups of mice (Online Figure IIIA) . The number of CD11c low F4/80 + cells (macrophages) was not altered by GM-CSF deficiency (Online Figure IIIB) . However, as reported in a previous study, 13 we found a modest (≈20%) but statistically significant decrease in the CD11c hi MHCII hi cell population, presumably DCs, in the double knockout plaques (Online Figure IIIB) . There was also a decrease in T cells in the Csf2 Figure IIIB) . Note that GM-CSF deficiency was not associated with significant changes in the peripheral blood monocyte or neutrophil count (Online Figure IIIC) .
We next examined necrotic area in the lesions because this end point represents a critical advanced lesional characteristic that determines plaque vulnerability in human atherosclerotic lesions. 15 There was an ≈50% decrease in the necrotic area in the GM-CSF-deficient mice ( Figure 1A and 1C). Atherosclerotic plaque necrosis is mediated in large part by the combination of lesional cell apoptosis and defective apoptotic cell clearance (efferocytosis). 23 To measure apoptosis, we used the TUNEL staining method and found that the absolute number and percentage of TUNEL-positive lesional cells were significantly lower in the GM-CSF-deficient mice (Figure 2A-2C) . The percentage of lesional cells that were positive for cleaved caspase-3, another marker of apoptosis, were also significantly lower in the GM-CSF-deficient mice ( Figure 2D ; Online Figure IV ). This decrease in lesional cell apoptosis in GM-CSF-deficient mice was because of lower numbers and percentages of apoptotic macrophages and DCs, whereas the extent of smooth muscle cell apoptosis was similar between the 2 groups of mice (Online Figure V) . Moreover, the ratio of apoptotic cells associated with macrophage phagocytes versus those that were free of phagocytes was similar between the 2 groups of mice ( Figure 2E ), which indicates that efferocytosis was not affected by GM-CSF deficiency. Two other features of advanced atherosclerosis thinning of the fibrous cap and decreased intimal elastin content were not affected by GM-CSF deficiency (Online Figure VIA and VIB). Thus, GM-CSF deficiency specifically decreases lesional macrophage and DC apoptosis and plaque necrosis in advance aortic root lesions of WD-fed Ldlr −/− mice, which suggested to us a specific mechanism of action.
GM-CSF-Deficient Mice Have Decreased Lesional Cytokines, Including IL-23
To understand the mechanism of decreased apoptosis in the lesions of GM-CSF-deficient mice, we tested several possibilities. Figure V) . In addition, cultured DCs and macrophages exposed to atherosclerosis-relevant proapoptotic factors such as 7-ketocholesterol (7KC) and oxidized low-density lipoprotein showed similar susceptibility to apoptosis (data not shown). A decrease in apoptosis-susceptible neutrophils in the double knockout lesions could also provide an explanation, but the lesions from the 2 groups of mice had similarly low numbers of neutrophils (Online Figure IIIB) . Thus, the decrease in lesional apoptosis in Csf2
Ldlr
−/− lesions cannot be explained by an increase in the ratio of apoptosisresistant:apoptosis-susceptible cell types.
We next examined whether the lesions of Csf2
Ldlr −/− mice had an alteration in cytokines that may lead to a decrease in apoptosis. The mRNA levels of pro-and anti-inflammatory cytokines in the lesions of the 2 groups of mice were quantified by reverse transcriptase quantitative polymerase chain reaction of lesional RNA obtained by laser capture microdissection. We found a significant decrease in the expression of interferon-γ and IL-2 in the GM-CSF-deficient lesions ( Figure 3A ), consistent with a decrease in lesional T cells (above). Further analysis of T-cell subset mRNA expression indicated a significant decrease in lesional Th1 and Th17 profiles, whereas Th2 and Tregs were unaffected ( Figure 3B ). The decrease in lesional Th1 cells is consistent with 
−/− mice, expression of the mRNA for IL-17A, the major cytokine produced by Th17 cells, was also decreased in the lesions of this cohort ( Figure 3A) . Previous studies have shown that IL-23, a cytokine induced by GM-CSF, is critical for Th17-cell differentiation and survival. 3, 24 In agreement with these reports, we found decreased levels of IL-23 in the double knockout lesions ( Figure 3A and in cardiomyocytes after ischemia-reperfusion injury, 26 whereas IL-23 has been reported to play a role in apoptosis of self-reactive thymocytes during T-cell selection 27 and of leukemic cells in B-acute lymphoblastic leukemia. 28 We therefore tested whether IL-17 or IL-23 could induce apoptosis in cultured macrophages under basal conditions or when exposed to 7KC, a proapoptotic oxysterol present in human atherosclerotic lesions. 29, 30 Apoptosis was assessed by annexin-V staining, which labels externalized phosphatidylserine on the plasma membrane of apoptotic cells. Treatment of macrophages with IL-17 or IL-23 alone did not lead to a significant increase in the number of annexin-V+ cells ( Figure 4A and 4B). Similarly, treatment of macrophages with IL-17 did not result in enhancement of 7KC-induced apoptosis ( Figure 4A ). However, IL-23 treatment led to a significant, dose-dependent increase in 7KC-induced macrophage apoptosis ( Figure 4B ; Online Figure XI), and this effect was abrogated by coincubation with a neutralizing antibody against the IL-23 receptor ( Figure 4C ). The neutralizing effect of the IL-23 receptor antibody was validated by demonstrating blockage of IL-23-induced STAT3 phosphorylation in cultured macrophages (data not shown). IL-12 and IL-23 share a common subunit and certain common functions, 31 but IL-12 did not enhance macrophage apoptosis ( Figure 4C ). The effect of IL-23 in sensitizing macrophages to apoptosis was not specific to 7-KC: both oxidized low-density lipoprotein 32 and the combination of an endoplasmic reticulum stressor and oxidized phospholipid (thapsigargin and KOdiA-PC) 33 gave similar results (Online Figure XII) . In contrast, tumor necrosis factor-α, IL-2, interferon-γ, and IL-6, which are higher in the lesions of Ldlr −/− versus Csf2
Ldlr −/− mice, did not increase basal or 7KC-induced apoptosis susceptibility in cultured macrophages (Online Figure XIII) . Finally, consistent with our in vivo data that GM-CSF-deficient mice have decreased apoptosis of lesional DCs as well as macrophages, we 
IL-23 Promotes Ubiquitin-Mediated Degradation of the Cell Survival Protein Bcl-2
7KC induces apoptosis in macrophages via activation of the mitochondrial-caspase-9 pathway of apoptosis. 35 We therefore investigated whether this pathway might also be required in IL-23-mediated enhancement of 7KC-induced macrophage apoptosis. Caspase-9 is activated by proteolytic cleavage of the inactive, full-length protein (procaspase-9) into a shorter length active protease. 36 Because activated-caspase-9 protein is short lived in the 7KC-macrophage model, caspase-9 activation is measured by quantifying the disappearance of procaspase 9. We found that IL-23 treatment enhanced 7KC-mediated loss of procaspase-9 (Online Figure XVIIA) , indicating enhanced caspase-9 activation. Most importantly, knockdown of caspase-9 blocked apoptosis in 7KC-treated cells and prevented the IL-23 increment in apoptosis (Online Figure XVIIB) .
Although the 7KC+IL-23 result does not necessarily prove a direct role for caspase-9 in IL-23 enhancement of apoptosis, because this enhancement requires 7KC-induced apoptosis in the first place, these findings led us to explore further a protein that is known to affect the mitochondrial pathway of apoptosis, Bcl-2. 37 Bcl-2 was of additional interest because of a report showing that it can protect leukemia cells from IL-23-induced apoptosis. 28 In this context, we found that treatment of macrophages and DCs with IL-23, but not 7KC, led to a significant downregulation of Bcl-2 protein expression ( Figure 6A ; Online Figure  XVIIIA) . IL-23 did not decease Bcl2 mRNA (Online Figure  XVIIIB) , indicating that the observed decrease in Bcl-2 protein is not because of transcriptional inhibition or decrease in mRNA stability. We next determined whether the decrease in Bcl-2 was regulated by proteasome-mediated degradation, which has been demonstrated in other settings in which Bcl-2 levels are regulated. 38 Consistent with this mechanism, MG-132, a proteasome inhibitor, abrogated the IL-23-mediated decrease in Bcl-2 ( Figure 6B) . One of the mechanisms by which Bcl-2 is targeted for proteasomal degradation is via dephosphorylation of Ser87, which serves as a signal for polyubiquitination by ubiquitin ligases. 38 Because ubiquitination of endogenous proteins is difficult to detect, we overexpressed full-length mouse Bcl-2 in control and IL-23-treated macrophages and then conducted an immunoprecipitation-immunoblot experiment. The data show a significant decrease in phospho-Ser-Bcl-2 in IL-23-treated macrophages compared with control cells ( Figure 6C , middle blot). Moreover, when the same lysates were immunoblotted for ubiquitin, we found that there was an increase in highmolecular weight bands between 50 and 150 kDa in the extracts from IL-23-treated macrophages, indicating that IL-23 promotes polyubiquitination of Bcl-2 ( Figure 6C, lower blot) . Thus, the ability of IL-23 to promote Bcl-2 dephosphorylation and subsequent ubiquitination is a plausible mechanism for IL-23-mediated Bcl-2 downregulation.
IL-23 Downregulates Bcl-2 and Enhances Apoptosis Susceptibility by Inducing MitogenActivated Protein Kinase Phosphatase-1-Mediated Suppression of Extracellular Signal-Related Kinase
Phosphorylation of Bcl-2 is mediated by extracellular signalrelated kinase (ERK), 38 and so we tested whether the decrease in phospho-Bcl-2 by IL-23 is caused by a decrease in ERK activity. Consistent with this scenario, we observed that IL-23 treatment was associated with a decrease in the level of phospho-ERK, the active form of ERK ( Figure 7A ). In addition, treatment of macrophages with an ERK inhibitor mimicked the effect of IL-23 on decreasing Bcl-2 protein (Online Figure  XIXA) . The decrease in phospho-ERK could be mediated by decreased phosphorylation by its upstream kinase MEK or by increased dephosphorylation by the phosphatases mitogenactivated protein kinase phosphatase-1 (MKP-1) or MKP-3. Whereas the level of active phospho-MEK in IL-23-treated macrophages was similar to that in control cells (Online Figure  XIXB) , MKP-1 protein was increased in IL-23-treated macrophages ( Figure 7B ). MKP-3 levels were similar between the 2 groups of macrophages (data not shown). We next tested whether the increase in MKP-1 expression was causally related to ERK dephosphorylation, Bcl-2 degradation, and increased apoptosis susceptibility in IL-23-treated macrophages using MKP-1 small interfering RNA. As predicted by the hypothesis that MKP-1 is a key upstream mediator in the IL-23 pathway, silencing MKP-1 abrogated the decrease in phospho-ERK and Bcl-2 expression ( Figure 7C ). Most importantly, knockdown of MKP-1 protected macrophages from the increment in apoptosis observed in IL-23/7KC-treated macrophages compared with 7KC-treated macrophages ( Figure 7D) .
To 
IL-23-MKP-1 Pathway Enhances Reactive Oxygen Species in 7KC-Treated Macrophages and in Advanced Atherosclerotic Lesions
Oxidative stress and the generation of various reactive oxygen species (ROS) and ROS-modified proteins and lipids are key features of advanced plaque progression. 39, 40 In cultured primary macrophages exposed to atherorelevant factors, including 7KC, ROS mediated by NADPH oxidase promotes apoptosis. 29, 30 Interestingly, one of the mechanisms by which Bcl-2 can exert its antiapoptotic activity is via its role as an antioxidant. 41, 42 In the context of these previous findings, we hypothesized that the IL-23-induced decrease in Bcl-2 might result in enhanced ROS generation, which in turn would further drive apoptosis susceptibility in macrophages exposed to atherorelevant proapoptotic factors. To address this hypothesis, we incubated macrophages with 7KC in the absence or presence of IL-23 and then probed the cells with CellROX Deep Red, which fluoresces in the cytoplasm when exposed to ROS. 43 Similar to the apoptosis findings, IL-23 alone did not induce ROS in macrophages, but it enhanced ROS in the presence of 7KC ( Figure 8A ; Online Figure XXIIIA) . In contrast, IL-23 did not affect 7KC-induced ROS in the mitochondria (data not shown), which was assayed using the mitochondrial ROS probe mitoSOX. 40 Next, to assess whether the increase in ROS on IL-23 treatment was a consequence of the decrease in Bcl-2, 41, 42 , we blocked Bcl-2 degradation using Mkp1 small interfering RNA (above). We found that the increment in ROS that occurs when IL-23 is added to 7KC-treated macrophages was abrogated by silencing MKP-1 ( Figure 8B ; Online Figure  XXIIIB) . Conversely, silencing Bcl2 mimicked IL-23 in terms of its ability to increase the ROS response in 7KC-treated macrophages ( Figure 8C ; Online Figure XXIIIC and XXIIID). The question as to whether the IL-23-mediated increment in ROS is causally important in its ability to enhance apoptosis susceptibility in 7KC-treated macrophages is difficult to address, because blocking ROS in these cells, for example, using NADPH oxidase 2-deficient macrophages, blocks 7KC-induced apoptosis, 30 which by itself would negate the IL-23 effect. Nonetheless, we did find that IL-23 was unable to enhance apoptosis above the suppressed level seen in 7KC-treated NADPH oxidase 2-deficient macrophages (data not shown). Finally, to determine the relevance of these findings in atherosclerosis, we analyzed lesional ROS by staining aortic root sections obtained from WD-fed Ldlr −/− and Csf2 −/− Ldlr −/− mice with the fluorescent superoxide sensor dihydroethidium. Consistent with the cultured macrophage data, we observed decreased dihydroethidium staining in the lesions of GM-CSF-deficient mice ( Figure 8D ; Online Figure  XXIVA) . Moreover, similar to the lesional apoptosis data in Figure 5D , this decrease in lesional ROS in the Csf2
mice was reversed by treating the mice with a restorative level of recombinant mouse IL-23 ( Figure 8E ; Online Figure  XXIVB ). These combined findings support a model in which the GM-CSF-IL-23-MKP-1 pathway promotes the degradation of Bcl-2, which increases apoptosis susceptibility by activating the mitochondrial-caspase 9 pathway of apoptosis as well as by enhancing ROS accumulation ( Figure 8F ).
Discussion
Earlier studies examining the function of GM-CSF in atherosclerosis have focused on its roles in myeloid cell differentiation and proliferation. For example, GM-CSF was demonstrated to be essential for the proliferation of CD11c hi cells in nascent atherosclerotic lesions, 44 which is consistent with the ability of GM-CSF to stimulate the differentiation of cultured DCs. However, a recent study demonstrated that GM-CSF is not necessary for differentiation of inflammatory DCs derived from monocytes. 45 Thus, it is possible that GM-CSF affects a specific subset of resident conventional DCs in the subendothelial space of healthy arteries or the intima of early atherosclerotic lesions. Consistent with this idea, we observed only a modest decrease in CD11c hi MHC-II hi DCs in established atherosclerotic lesions of GM-CSF-deficient mice.
In terms of atherosclerosis per se, the role of GM-CSF seems to be influenced by the model used and the focus of the study. In particular, studies using mice that completely lack apolipoprotein E in all cells or in bone marrow-derived cells, which is known to affect immune cell function 46, 47 and hematopoietic stem cell proliferation 48 have shown complex effects that may be specific to models lacking apolipoprotein E. As an example of the complexity, exogenous administration of GM-CSF to Apoe −/− mice was reported to increase atherosclerotic lesion size, 14 whereas deficiency of GM-CSF in an Apoe −/− background was also associated with larger lesion size and increased macrophage content, which was attributed to a decrease in macrophage perixosome proliferator-activated receptor (PPAR)-γ and ABCA1. 7 In contrast, in WD-fed Ldlr −/− model used here, which has lipoprotein profiles similar to dyslipidemic humans and do not have adverse immune effects, GM-CSF deficiency did not affect macrophage Pparg, Abca1, or Abcg1 expression in lesional macrophages (unpublished data). Moreover, in WD-fed Ldlr −/− mice, we found that GM-CSF deficiency had no significant effect on aortic root lesion size per se, which agrees in principle with another group showing only a modest effect in females but not in males. 13 Rather, as demonstrated here, the dominant effect of GM-CSF in Ldlr −/− mice is enhancement of macrophage apoptosis in advanced atherosclerosis by a specific mechanism related to its ability to induce IL-23 production.
The results of the current study underscore the importance of the cytokine-inducing role of GM-CSF in atherosclerosis, which in this case involves a particular cytokine, IL-23, that promotes macrophage apoptosis. Under physiological conditions, GM-CSF-induced production of IL-23 and subsequent macrophage apoptosis may act as a feedback mechanism to control immune cell populations or to prevent excessive inflammation. In that setting, the apoptotic macrophages would be rapidly cleared by neighboring phagocytes (efferocytosis), which prevents both secondary necrosis and generation of proinflammatory damage-associated molecular patterns and also activates anti-inflammatory signaling pathways in the efferocytes themselves. 49 However, in advanced atherosclerotic lesions, efferocytosis is defective, 50 and so processes that increase apoptosis promote necrosis and inflammation, which, as demonstrated here, is the case with GM-CSF-induced IL-23.
The link between GM-CSF and IL-23 has been explored most extensively in the setting of autoimmune disorders, where a GM-CSF/IL-23/Th17 axis has been demonstrated to play a major role in disease exacerbation. 3, 24 Accordingly, anti-GM-CSF, anti-IL-23, and anti-IL-17 therapies are currently under investigation for treatment of these diseases. 12, 51 In these disorders, mechanistic studies have focused on the role of IL-23 in promoting Th17-cell survival and Th17-mediated IL-17 production. In advanced atherosclerosis, however, the pathogenic effect of IL-23 seems to be largely independent of IL-17 generation, as neutralization of IL-17 activity did not block IL-23-induced macrophage apoptosis or plaque necrosis. Moreover, IL-23, but not IL-17, increased apoptosis in 7KC-treated macrophages. IL-23 has been shown previously to induce apoptosis in self-reactive thymocytes, 27 and, at high concentration, in B-acute lymphoblastic leukemia cells. 28 In B-acute lymphoblastic leukemia cells, like macrophages, the proapoptotic mechanism of IL-23 involves downregulation of Bcl-2. In B-acute lymphoblastic leukemia cells, however, Bcl-2 downregulation is mediated by a microRNA, miR15a, 28 whereas in macrophages, Bcl-2 downregulation is mediated by the proteasome after MKP-1-mediated Bcl-2 dephosphorylation.
Our laboratory has previously shown that atherosclerosisprone mice lacking macrophage Bcl-2 have increased lesional macrophage apoptosis and increased necrotic area, 52 which demonstrates that Bcl-2 is critical for macrophage survival in advanced atherosclerosis. The current study provides a pathophysiolgically relevant context for this effect, namely, GM-CSF/IL-23-mediated downregulation of macrophage Bcl-2. The classic role of Bcl-2 is suppression of the mitochondrial-caspase-9 pathway of apoptosis, 37 but our data as well as previous studies 41, 42 suggest that Bcl-2 can also suppress intracellular oxidant stress. Given the role of ROS in macrophage apoptosis, 18 we propose the GM-CSF/IL-23 pathway, through destabilizing Bcl-2, promotes apoptosis susceptibility in macrophages by increasing both caspase-9 activity and intracellular ROS. The precise mechanism through which Bcl-2 regulates intracellular ROS in other models is not well understood, but there is evidence that it may involve upregulation of superoxide dismutase and catalase, 42 as well as direct binding to the antioxidant GSH. 53 How Bcl-2 regulates cytosolic ROS in macrophages in the setting of advanced atherosclerosis will require further study, but we speculate it may involve suppression of NADPH oxidase. 30, 54 Stimuli other than GM-CSF might also increase the generation of IL-23 by macrophages and DCs in atherosclerotic lesions. For example, IL-23 production by DCs is induced by the endoplasmic reticulum stress effector C-EBP homologous protein (CHOP), which binds to a specific promoter region on IL-23 gene. 55 We have demonstrated previously that endoplasmic reticulum stress-induced CHOP plays an important role in macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions. 56 Whether the proapoptotic effects of endoplasmic reticulum stress on lesional macrophages is mediated, in part, via induction of IL-23 remains to be explored. In addition, Ataxia telangiectasia mutated kinase represses production of IL-23 by DCs, 57 and atherosclerosis is exacerbated in mice lacking Ataxia telangiectasia mutated 58 and in humans with single nucleotide polymorphisms 59 or mutations in Ataxia telangiectasia mutated. 60 The potential link between these observations and excessive IL-23 production thus represents another area of future investigation based on the new findings and pathway described herein.
The results of several preclinical studies and a small human study raise the possibility that exogenously administered recombinant GM-CSF might be proatherogenic and promote coronary artery disease (CAD). 9, 10, 14 The current data raise the possibility that GM-CSF-induced IL-23 could be involved in these findings. Indeed, a small human study comparing serum IL-23 and IL-17 levels in patients with CAD versus healthy subjects demonstrated that serum IL-23 levels were associated strongly with CAD. 61 This association requires replication and could simply reflect a noncausative, marker-related phenomenon, but the data herein raise the possibility that IL-23 itself could be causative. With these studies in mind, and given the mechanistic insight of the current study, it would be interesting to determine whether patients receiving anti-IL-23 therapy for the treatment of rheumatoid arthritis accrue additional cardiovascular benefits because of decreased plaque necrosis. If so, one could imagine a future therapeutic strategy in which IL-23 or its downstream proapoptotic mediators are neutralized in high-risk patients with the goal of preventing plaque necrosis and subsequent acute cardiovascular clinical events.
